Welcome to the October edition of MPN Updates! In this issue, we provide highlights that emanated from Perspectives on the Collaborative Management of Myeloproliferative Neoplasms, a recent roundtable discussion held in Houston, Texas. Panelists discussed current topics such as the updated 2016 WHO classification of myeloproliferative neoplasms and therapies available for managing complications related to the disease processes. You can view the full video here.
This edition also provides articles on such topics as the utilization of ruxolitinib to control hematocrit levels in polycythemia vera, chromothripsis as a recurrent genomic abnormality in patients with high-risk myelodysplastic syndromes, and bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera. In our next edition, we plan to provide you with findings from the 7th International Conference on Myeloproliferative Neoplasms being held in Estoril, Portugal.
Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at email@example.com at any time.
Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus